Last reviewed · How we verify
BL-B01D1 for Injection
BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway.
BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway. Used for Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available..
At a glance
| Generic name | BL-B01D1 for Injection |
|---|---|
| Also known as | iza-bren, izalontamab brengitecan, BMS-986507 |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
However, the exact mechanism of action is not well-documented, and further research is needed to fully understand its effects.
Approved indications
- Phase 2 clinical trials for BL-B01D1 for Injection are ongoing, but specific indications are not publicly available.
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors (PHASE2)
- A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies (PHASE1, PHASE2)
- A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma (PHASE2)
- A Study of BL-B01D1 in Patients With Recurrent Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |